Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia

NCT00143975 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00143975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
June 30, 2009
Enrollment
95 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute